ELDRED KARY 4

What Happened Kary Eldred, a director of Galectin Therapeutics (GALT), reported a purchase of 300 shares on February 6, 2026. The shares were acquired at $2.70 each for a total reported purchase value of $810. This was a purchase (transaction code P), which represents an insider buy rather than a sale.

Key Details

• Transaction date: 2026-02-06; Filing date: 2026-02-09 (timely filing).
• Price and quantity: 300 shares at $2.70 per share; total = $810.
• Transaction type: P = Purchase (open market or private purchase as reported).
• Shares owned after the transaction: Not specified in the provided filing.
• Footnotes:
  • F1 — These shares are held of record by Eldred as custodian for a minor under the Uniform Transfer to Minors Act; Eldred disclaims beneficial ownership.
  • F2 — These shares are also held in a special needs trust for which Eldred is trustee; Eldred disclaims beneficial ownership.
• No indication of a 10b5-1 plan, option exercise, gift, or tax-withholding event in this filing.

Context The reported purchase is small in dollar value ($810) and appears to reflect shares held in custodial/trust capacities rather than direct beneficial ownership by the director. Purchases can be informative to investors, but the filing’s footnotes clarify Eldred disclaims beneficial ownership of these specific shares.